Dong Chen
Department of Immunology, MD Anderson Cancer Center, Houston, Texas 77030, USA.
J Immunotoxicol. 2008 Jan;5(1):43-6. doi: 10.1080/15476910801897953.
CD4+ T-lymphocytes are pivotal in immune responses to pathogens and in pathogenesis of various inflammatory diseases. Upon activation by the innate immune system, naïve CD4+ helper T (T(H))-lymphocytes differentiate into effector cells that are characterized by their cytokine profiles. T-Helper 1 (T(H)1) and T(H)2 lymphocytes have long been regarded as two sides of a coin in adaptive immune responses. However, recent data indicate a novel lineage of T(H) lymphocytes specified by the production of interleukin-17 (IL-17). Here I describe the recent literature on the regulatory mechanisms underlying generation of IL-17-expressing T-lymphocytes. In addition, I also summarize on the biological function of these cells in infection, autoimmunity and allergy. IL-17 and IL-17-expressing inflammatory T(H) lymphocytes may thus serve as good targets for therapeutic intervention in treatment of patients with inflammatory diseases.
CD4+ T淋巴细胞在针对病原体的免疫反应以及各种炎症性疾病的发病机制中起着关键作用。在天然免疫系统激活后,初始CD4+辅助性T(T(H))淋巴细胞分化为效应细胞,这些效应细胞以其细胞因子谱为特征。长期以来,辅助性T1(T(H)1)淋巴细胞和辅助性T2淋巴细胞在适应性免疫反应中被视为同一硬币的两面。然而,最近的数据表明,白细胞介素-17(IL-17)的产生可确定一种新的辅助性T淋巴细胞谱系。在此,我描述了关于产生IL-17的T淋巴细胞生成的调控机制的最新文献。此外,我还总结了这些细胞在感染、自身免疫和过敏中的生物学功能。因此,IL-17以及表达IL-17的炎症性辅助性T淋巴细胞可能是炎症性疾病患者治疗干预的良好靶点。